OUR HERITAGE
From prebiotic innovation to host-centred postbiotic science.
Before establishing veMico, our founders contributed to the development, scientific evaluation and commercialisation of Bimuno prebiotic technology. At veMico, their work extends towards characterising biologically active microbial components and developing defined postbiotic preparations. VMK223 is the first commercially developed ingredient from this programme.
That progression — from investigating how prebiotics influence microbial populations to researching microbiota–host interactions and characterised microbial bioactives — explains the company’s focus today.
FOUNDERS’ PRIOR EXPERIENCEScientific foundations
Founders’ expertise in microbial ecology, prebiotic science and microbiota–host interactions.
FOUNDERS’ PRIOR EXPERIENCEBimuno development
Earlier contributions to scientific research, clinical investigation and commercial translation of Bimuno technology.
veMico · INCORPORATED 2018veMico established
veMico was incorporated in 2018 and became operational in 2019, developing its own postbiotic ingredient research programme.
veMico TECHNOLOGYVMK223 commercialisation
Development of a characterised ingredient with published standalone human evidence and examples in finished products.
